Med24
Clinical Medicine 14. 10. 2026 • 2 min read • medical-news

Does Stool-Based Test Detect Colorectal Cancer as Well in Women?

At the standard positivity threshold, fecal immunochemical testing (FIT) is likely to miss more colorectal cancers (CRCs) and advanced precancerous lesions (APLs) in women versus men, a retrospective analysis suggested. Among...

Does Stool-Based Test Detect Colorectal Cancer as Well in Women?

A retrospective analysis suggests that at the standard positivity threshold, fecal immunochemical testing (**FIT**) is likely to miss more colorectal cancers (**CRCs**) and advanced precancerous lesions (**APLs**) in women compared to men. Among more than 30,000 screening participants, men exhibited higher fecal hemoglobin levels and **FIT** sensitivities for CRCs and APLs. Specifically, mean fecal hemoglobin levels were 955 ng/mL for women versus 1,541 ng/mL for men (P=0.03) for CRCs, and 174 and 230 ng/mL, respectively (P<0.001) for APLs. At a 100 ng/mL threshold, men demonstrated higher sensitivities for both CRCs (77.4%) and APLs (25.8%) compared to women (62% and 20.2%, respectively) with P=0.03 and P<0.001. However, men also showed slightly lower specificity (94.2%) than women (95.3%) (P<0.001).

Sponsored content

To achieve men’s CRC sensitivity, a lower **FIT** threshold of 12 ng/mL would be required for women, resulting in a specificity of 75.7%. Similarly, to meet APL sensitivity, a threshold of 65 ng/mL would be needed for women, yielding a specificity of 92.8%. Reaching 95% specificity would necessitate thresholds of 120 ng/mL for men and 94 ng/mL for women. The analysis utilized data from the DeeP-C and **BLUE-C** studies, involving 30,165 participants (mean age 63.4 years, 53.4% women) with 0.54% having CRC and 9.6% having APLs. Differences in CRC and APL distribution were observed between sexes; women had a higher proportion of proximal CRCs (48.1%) and APLs (61.2%) compared to men, accompanied by lower sensitivities at the 100 ng/mL threshold (50% vs 80.8% and 12.8% vs 17.7%, respectively). A multivariable analysis indicated that male sex, smoking, a **BMI** of 30 or greater, larger lesion size, and distal/rectal location were independently associated with FIT sensitivity for advanced neoplasia. Imperiale noted that maximizing sensitivity is a primary goal in screening programs, but a trade-off exists, and understanding performance and long-term outcomes is crucial.”}

Original Scientific Source
medical-news
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Advertisement